Limited data exist on outcomes in mRCC patients with major venous involvement (MVI). Assessment of impact of a given variable on prognosis in cancer patients is challenging given competing causes of ...
Immunotherapy with immune checkpoint inhibitors is standard first-line treatment for advanced renal cell carcinoma (RCC), but ...
Key findings on renal cell carcinoma (RCC) presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium include the final results of the CheckMate 9ER and COSMIC-313 ...
A study from the University of Michigan Health Rogel Cancer Center and Department of Pathology shows that further testing in ...
Merck and Eisai report Phase 3 results showing Welireg plus Lenvima significantly improved progression-free survival in ...
Phase I Study Combining Treatment With Temsirolimus and Sunitinib Malate in Patients With Advanced Renal Cell Carcinoma This phase I study evaluated temsirolimus in combination with sunitinib in ...
Surgery Versus Ablation for Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF-RCT Trial) and a Nonrandomized Prospective Observational Trial (SURF-Cohort Trial) While immune checkpoint ...
Efficacy of second line (2L) treatment with tivozanib (Tivo) as monotherapy or with nivolumab (Nivo) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with an immune ...
Xencor's clear cell renal cell carcinoma treatment demonstrated evidence of anti-tumor activity in a phase 1 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback